Platelet kinetics in patients with chronic immune thrombocytopaenia treated with thrombopoietin receptor agonists
European Journal of Haematology · 2023
DOI: 10.1111/ejh.13929 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Zlatko Pravdic und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Haematology, University Clinical Centre of Serbia, Belgrade, Serbia. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Introduction
Thrombopoietin receptor agonists (TPO‐RAs) increase platelet counts (PC) in the majority of patients with chronic immune thrombocytopaenia (ITP). Platelet kinetics study (PKS) might contribute to the understanding of mechanisms that lead to durable response.
Objectives
To evaluate the effects of TPO‐RAs on PKS parameters in chronic ITP patients.
Methods
Fifteen chronic ITP patients, aged 59 years [range: 22–84], female/male: 10/5, splenectomised 7/15, were treated with TPO‐RAs (eltrombopag/romiplostim: 11/4). Durable response was defined as PC ≥30 × 10 9 /L at 6 months. Autologous 111 Indium‐oxinate PKS was performed before and 5 months after TPO‐RAs initiation. Accordingly, platelet survival (PS), platelet turnover, production ratio and sequestration site were assessed.
Results
Durable response was achieved in 13/15 of patients (eltrombopag/romiplostim: 10/3). Pre‐treatment parameters were: PC 10 × 10 9 /L [range: 1–110], PS 0.5 days [range: 0.1–1.7 (normal values: 7–10)], platelet turnover 30 857 Plt/μL/day [range: 944–103 500] and platelet production ratio 0.64 [range: 0.01–3.2 (normal values: 1 ± 0.2)]. Post‐treatment assessment showed significantly higher: PC 92.5 × 10 9 /L [range: 28–260, p = .001], PS 2.2 days [range: 0.1–3.6, p = .008], platelet turnover 70 213 Plt/μL/day [range: 2800–462 236, p = .02] and platelet production ratio 1.8 [range: 0.5–37.9, p = .011] compared to the pre‐treatment values. Platelet sequestration site altered in 3/15 treated with TPO‐RAs.
Conclusions
TPO‐RAs could increase PC by simultaneous increasing of platelet production and decreasing of platelet destruction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinic of Haematology, University Clinical Centre of Serbia, Belgrade, Serbia.
- Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- Clinic of Haematology, Clinical Centre of Kragujevac, Kragujevac, Serbia.
- Faculty of Medicine, University of Kragujevac, Kragujevac, Serbia.
- Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
- Centre of Nuclear Medicine, Clinical Centre of Serbia, Belgrade, Serbia.
ORCID-Profile: Zlatko Pravdic, Mirjana Mitrovic
Zitieren
APA
Pravdic, Z., Suvajdzic-Vukovic, N., Djurdjevic, P., Pantic, N., Bukumiric, Z., Virijevic, M., Todorovic-Tirnanic, M., Thachil, J., & Mitrovic, M. (2023). Platelet kinetics in patients with chronic immune thrombocytopaenia treated with thrombopoietin receptor agonists. European Journal of Haematology. https://doi.org/10.1111/ejh.13929
Vancouver
Pravdic Z, Suvajdzic-Vukovic N, Djurdjevic P, Pantic N, Bukumiric Z, Virijevic M, et al. Platelet kinetics in patients with chronic immune thrombocytopaenia treated with thrombopoietin receptor agonists. European Journal of Haematology. 2023. doi:10.1111/ejh.13929
BibTeX
@article{Pravdic2023,
author = {Pravdic, Zlatko and Suvajdzic-Vukovic, Nada and Djurdjevic, Predrag and Pantic, Nikola and Bukumiric, Zoran and Virijevic, Marijana and Todorovic-Tirnanic, Mila and Thachil, Jecko and Mitrovic, Mirjana},
title = {Platelet kinetics in patients with chronic immune thrombocytopaenia treated with thrombopoietin receptor agonists},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.13929}
}
EUVIMED